Cargando…

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Recurrent gene mutations and fusions in cancer patients are likely to be associated with cancer progression or recurrence by Vogelstein et al. (Science (80-) 340, 1546–1558 (2013)). In this study, we investigated gene mutations and fusions that recurrently occurred in early-stage cancer patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Su Han, Yoon, Shinkyo, Lee, Dae Ho, Kim, Sang-We, Kim, Kwoneel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486871/ https://www.ncbi.nlm.nih.gov/pubmed/34599262 http://dx.doi.org/10.1038/s41598-021-99197-w

Ejemplares similares

Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
por: Roh, Yun Hwa, et al.
Publicado: (2023)

Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study
por: Choi, Myeong Geun, et al.
Publicado: (2021)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Impact of idiopathic pulmonary fibrosis on recurrence after surgical treatment for stage I–III non-small cell lung cancer
por: Song, Myung Jin, et al.
Publicado: (2020)

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients
por: Lu, Yan, et al.
Publicado: (2012)

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer
por: Yoon, Shinkyo, et al.
Publicado: (2022)

A Case of Residual Non-Small Cell Lung Cancer Cells Coexisting With Newly Developed Small Cell Lung Cancer Cells in Ascitic Fluid after Chemotherapy for Non-Small Cell Lung Cancer
por: Park, Sang Hyuk, et al.
Publicado: (2014)

Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer
por: Lee, Sang Hee, et al.
Publicado: (2015)

Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer
por: Kim, Yeon Joo, et al.
Publicado: (2015)

Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment
por: Jang, Yoon Jung, et al.
Publicado: (2023)

Prognosis of Recurrence after Complete Resection in Early-Stage Non-Small Cell Lung Cancer
por: Choi, Pil Jo, et al.
Publicado: (2013)

Negative Effect of Reduced NME1 Expression on Recurrence-Free Survival in Early Stage Non-Small Cell Lung Cancer
por: Kim, Dohun, et al.
Publicado: (2020)

Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer
por: Wu, Ching-Feng, et al.
Publicado: (2015)

Pneumonectomy for Clinical Stage I Non-Small Cell Lung Cancer in Elderly Patients over 70 Years of Age
por: Kim, Tae Ho, et al.
Publicado: (2015)

Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
por: Kim, Dal Yong, et al.
Publicado: (2011)

Recurrence Risk Factors Analysis for Stage I Non-small CellLung Cancer: Erratum
Publicado: (2015)

Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
por: Tsutani, Yasuhiro, et al.
Publicado: (2021)

Treatment outcomes of passive scattering proton beam therapy for stage I non-small cell lung cancer
por: Bayasgalan, Unurjargal, et al.
Publicado: (2021)

Network perturbation by recurrent regulatory variants in cancer
por: Jang, Kiwon, et al.
Publicado: (2017)

Identification of recurrence-associated microRNAs in stage I lung adenocarcinoma
por: Sim, Jongmin, et al.
Publicado: (2018)

An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma
por: Kim, Yeseul, et al.
Publicado: (2023)

Prognosis of multi‐level N2‐positive non‐small cell lung cancer according to lymph node staging using endobronchial ultrasound‐transbronchial biopsy
por: Yoon, Hee‐Young, et al.
Publicado: (2018)

Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer
por: Jin, Ying, et al.
Publicado: (2013)

Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR
por: Choi, Yoon Ji, et al.
Publicado: (2015)

A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
por: Lu, Yan, et al.
Publicado: (2006)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

Pattern of Recurrence after Curative Resection of Local (Stage I and II) Non-Small Cell Lung Cancer: Difference According to the Histologic Type
por: Choi, Yong Soo, et al.
Publicado: (2004)

The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer
por: Lee, Jin Gu, et al.
Publicado: (2008)

Lobar emphysema ratio of more than 1% in the lobe with lung cancer as poor predictor for recurrence and overall survival in patients with stage I non-small cell lung cancer
por: Lee, Jeong Pyo, et al.
Publicado: (2023)

Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer
por: Jung, In-Hye, et al.
Publicado: (2015)

Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer
por: Harada, Hiroaki, et al.
Publicado: (2015)

Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2020)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
por: Shih, Jin-Yuan, et al.
Publicado: (2020)

Antigen Coverage Presented by MHC Class I Has a Negative Correlation with SARS-CoV-2-Induced Mortality
por: Park, Ji Soo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_210on8klra7ccimtcl6ivjm2lt